MYC and prostate carcinoma: In this study, we have identified a compound that is capable of impeding cell cycle re-entry by quiescent PTENnull/p53WT and PTENnull/p53mut prostate cancer cells, likely by promoting c-MYC protein degradation through stabilization of the E3 ubiquitin ligase FBXW7.